Jefferies analyst David Stanton has revised Mesoblast (MESO, Financial) from a Buy to a Hold rating. The new price target is set at A$2.60, an increase from the previous A$2.50, following the company's fiscal fourth-quarter performance. The firm calculates that during the quarter, 68 paid infusions of Ryoncil were administered in the U.S., with six patents seemingly completing their treatment cycle. Jefferies has also updated its fiscal 2025 estimates and is anticipating Mesoblast's annual results, due in August.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Mesoblast Ltd (MESO, Financial) is $27.00 with a high estimate of $30.00 and a low estimate of $24.00. The average target implies an upside of 118.80% from the current price of $12.34. More detailed estimate data can be found on the Mesoblast Ltd (MESO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Mesoblast Ltd's (MESO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Mesoblast Ltd (MESO, Financial) in one year is $1.30, suggesting a downside of 89.47% from the current price of $12.34. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Mesoblast Ltd (MESO) Summary page.
